Dr. Hoos on the Patients That Respond to Ipilimumab

Axel Hoos, MD, PhD
Published: Sunday, Jun 05, 2011



Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb describes that roughly 15% of patients have a response to ipilimumab by conventional criteria (which means to shrinking the tumor). Hoos notes that durability is the importance part of the findings with a median duration of 19 months.


Axel Hoos, MD, PhD, the medical lead in Immunology/Oncology at Bristol-Myers Squibb describes that roughly 15% of patients have a response to ipilimumab by conventional criteria (which means to shrinking the tumor). Hoos notes that durability is the importance part of the findings with a median duration of 19 months.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x